Global Familial Amyloid Polyneuropathy Therapeutics Market Report By Drug Type (Inotersen, Tafamidis, Patisiran), By Disease Type (Familial Amyloid Polyneuropathy-I (FAP-I), Familial Amyloid Polyneuropathy-II (FAP-II), Familial Amyloid Polyneuropathy-III (FAP-III)), By Gender Type (Male, Female), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies) And By Regions - Industry Trends, Size, Share, Growth, Estimation and Forecast, 2021-2028

Name: Global Familial Amyloid Polyneuropathy Therapeutics Market Report
Brand: Value Market Research
SKU: Healthcare
Price: 3950.00 USD
Availability: OnlineOnly
Rating: 4.2 (80 reviews)

ID:VMR11213724

April 2021

Report Formats: Electronic (PDF), MS EXCEL

Description
Table Of Content

The global demand for Familial Amyloid Polyneuropathy Therapeutics Market is presumed to reach the valuation of nearly USD XX MN by 2028 from USD XX MN in 2021 with a CAGR of XX% under the study period of 2022 - 2028.

Familial amyloid polyneuropathy (FAP) therapeutics includes specific treatments to treat the autosomal dominant genetic disorder caused by a systemic deposition of amyloid fibrils and characterized by progressive sensory, motor, and autonomic polyneuropathy. The primary treatment for FAP involves blocking the hepatic production of mutant and wild type transthyretin gene TTR. First-line specific treatment is liver transplantation to stop the neuropathy progression to double the survival rate. In cases of severe renal or cardiac insufficiency, a combined kidney–liver or heart–liver transplantation is proposed. In recent times transthyretin tetramer stabilizers to slow the progression of peripheral neuropathy are used. The use of nonsteroidal anti-inflammatory drugs and gene silencing has been proposed.

Market Dynamics

Rising awareness about FAP, a multi-visceral and life-threatening disease resulting in multiple disabilities, is the primary stimulant for this growth market. The development of innovative therapies and increased adoption of therapeutic drugs to treat this progressive disease affecting the peripheral and autonomic nervous system will boost the market growth. The multidisciplinary approach used in treating FAP will serve as a boon for this market's steady growth. The high survival rate in patients adopting a long-term follow-up of FAP therapeutics will boost market growth. The stringent government rules and regulations for therapeutics' approval, high cost involved in the research and development of new therapeutics will be the key barriers hampering this market.

The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.

Additionally, these tools also give inclusive assessment of each application/product segment in the global market of familial amyloid polyneuropathy therapeutics.

Market Segmentation

The report segments the anthracite market and analyses it with respect to the geography, intending to keep the marketer informed and help them identify the target demographics for the product or service.

By Drug Type

Inotersen
Tafamidis
Patisiran

By Disease Type

Familial Amyloid Polyneuropathy-I (FAP-I)
Familial Amyloid Polyneuropathy-II (FAP-II)
Familial Amyloid Polyneuropathy-III (FAP-III))

By Gender Type

Male
Female

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies

Regional Analysis

This section covers regional segmentation which accentuates on current and future demand for familial amyloid polyneuropathy therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.

Global Familial Amyloid Polyneuropathy Therapeutics Market Share by Region (Representative Graph)

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the familial amyloid polyneuropathy therapeutics market include Pfizer Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Corino Therapeutics Inc., Proclara Biosciences, Arcturus Therapeutics Inc. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE
       1.1. Report Description
           1.1.1. Objective
           1.1.2. Target Audience
           1.1.3. Unique Selling Proposition (USP) & offerings
       1.2. Research Scope
       1.3. Research Methodology
           1.3.1. Market Research Process
           1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY
       2.1. Highlights of Familial Amyloid Polyneuropathy Therapeutics Market
       2.2. Global Familial Amyloid Polyneuropathy Therapeutics Market Snapshot

3 . FAMILIAL AMYLOID POLYNEUROPATHY THERAPEUTICS – INDUSTRY ANALYSIS
       3.1. Introduction
       3.2. Market Drivers of Familial Amyloid Polyneuropathy Therapeutics Market
       3.3. Market Restraints of Familial Amyloid Polyneuropathy Therapeutics Market
       3.4. Opportunities of Familial Amyloid Polyneuropathy Therapeutics Market
       3.5. Trends of Familial Amyloid Polyneuropathy Therapeutics Market
       3.6. Porter’s Five Force Analysis of Familial Amyloid Polyneuropathy Therapeutics Market
       3.7. Familial Amyloid Polyneuropathy Therapeutics Market Attractiveness Analysis
           3.7.1 Market Attractive Analysis by Drug Type
           3.7.2 Market Attractive Analysis by Disease Type
           3.7.3 Market Attractive Analysis by Gender Type
           3.7.4 Market Attractive Analysis by Distribution Channel
           3.7.5 Market Attractive Analysis by Region

4 . VALUE CHAIN ANALYSIS
       4.1. Familial Amyloid Polyneuropathy Therapeutics Value Chain Analysis
       4.2. Familial Amyloid Polyneuropathy Therapeutics Raw Material Analysis
           4.2.1. List of Raw Materials
           4.2.2. Familial Amyloid Polyneuropathy Therapeutics Raw Material Manufactures List
           4.2.3. Price Trend of Familial Amyloid Polyneuropathy Therapeutics Key Raw Materials
       4.3. List of Potential Buyers
       4.4. Marketing Channel
           4.4.1. Direct Marketing
           4.4.2. Indirect Marketing
           4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK
       5.1. Impact Analysis of Covid-19 Outbreak on Familial Amyloid Polyneuropathy Therapeutics Market
           5.1.1. Direct Impact on Production
           5.1.2. Supply Chain and Market Disruption
           5.1.3. Financial Impact on Firms and Financial Markets
       5.2. COVID-19 Impact Analysis by Production, Import, Export and Demand
       5.3. Familial Amyloid Polyneuropathy Therapeutics Market: Pre V/S Post COVID-19
       5.4. Estimated Impact of the Coronavirus (COVID-19) Epidemic on the Familial Amyloid Polyneuropathy Therapeutics Market
       5.5. COVID-19: Micro and Macro Factor Analysis on Familial Amyloid Polyneuropathy Therapeutics Market

6 . GLOBAL FAMILIAL AMYLOID POLYNEUROPATHY THERAPEUTICS MARKET ANALYSIS BY DRUG TYPE
       6.1 Overview by Drug Type
       6.2 Historical Data 2016-2019
       6.3 Global Familial Amyloid Polyneuropathy Therapeutics Market Analysis by Drug Type
       6.4 Market Analysis of Inotersen by Regions
       6.6 Market Analysis of Tafamidis by Regions
       6.5 Market Analysis of Patisiran by Regions

7 . GLOBAL FAMILIAL AMYLOID POLYNEUROPATHY THERAPEUTICS MARKET ANALYSIS BY DISEASE TYPE
       7.1 Overview by Disease Type
       7.2 Historical Data 2016-2019
       7.3 Global Familial Amyloid Polyneuropathy Therapeutics Market Analysis by Disease Type
       7.4 Market Analysis of Familial Amyloid Polyneuropathy-I (FAP-I) by Regions
       7.5 Market Analysis of Familial Amyloid Polyneuropathy-II (FAP-II) by Regions
       7.6 Market Analysis of Familial Amyloid Polyneuropathy-III (FAP-III)) by Regions

8 . GLOBAL FAMILIAL AMYLOID POLYNEUROPATHY THERAPEUTICS MARKET ANALYSIS BY GENDER TYPE
       8.1 Overview by Gender Type
       8.2 Historical Data 2016-2019
       8.3 Global Familial Amyloid Polyneuropathy Therapeutics Market Analysis by Gender Type
       8.4 Market Analysis of Male by Regions
       8.5 Market Analysis of Female by Regions

9 . GLOBAL FAMILIAL AMYLOID POLYNEUROPATHY THERAPEUTICS MARKET ANALYSIS BY DISTRIBUTION CHANNEL
       9.1 Overview by Distribution Channel
       9.2 Historical Data 2016-2019
       9.3 Global Familial Amyloid Polyneuropathy Therapeutics Market Analysis by Distribution Channel
       9.4 Market Analysis of Hospital Pharmacies by Regions
       9.5 Market Analysis of Retail Pharmacies by Regions

10 . GLOBAL FAMILIAL AMYLOID POLYNEUROPATHY THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY
       10.1. Regional Outlook
       10.2. Introduction
       10.3. North America
           10.3.1. Overview and Historic Data
           10.3.2. North America Familial Amyloid Polyneuropathy Therapeutics Market Estimate By Market Segment
           10.3.3. North America Familial Amyloid Polyneuropathy Therapeutics Market Estimate By Country
           10.3.4. United State
           10.3.5. Canada
           10.3.6. Mexico
       10.4. Europe
           10.4.1. Overview and Historic Data
           10.4.2. Europe Familial Amyloid Polyneuropathy Therapeutics Market Estimate by Market Segment
           10.4.3. Europe Familial Amyloid Polyneuropathy Therapeutics Market Estimate by Country
           10.4.4. United Kingdom
           10.4.5. France
           10.4.6. Germany
           10.4.7. Italy
           10.4.8. Russia
           10.4.9. Rest Of Europe
       10.5. Asia Pacific
           10.5.1. Overview and Historic Data
           10.5.2. Asia Pacific Familial Amyloid Polyneuropathy Therapeutics Market Estimate by Market Segment
           10.5.3. Asia Pacific Familial Amyloid Polyneuropathy Therapeutics Market Estimate by Country
           10.5.4. China
           10.5.5. India
           10.5.6. Japan
           10.5.7. South Korea
           10.5.8. Australia
           10.5.9. Rest Of Asia Pacific
       10.6. Latin America
           10.6.1. Overview and Historic Data
           10.6.2. Latin America Familial Amyloid Polyneuropathy Therapeutics Market Estimate by Market Segment
           10.6.3. Latin America Familial Amyloid Polyneuropathy Therapeutics Market Estimate by Country
           10.6.4. Brazil
           10.6.5. Argentina
           10.6.6. Peru
           10.6.7. Chile
           10.6.8. Rest of Latin America
       10.7. Middle East & Africa
         10.7.1. Overview and Historic Data
           10.7.2. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutics Market Estimate by Market Segment
           10.7.3. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutics Market Estimate by Country
           10.7.4. Saudi Arabia
           10.7.5. UAE
           10.7.6. Israel
           10.7.7. South Africa
           10.7.8. Rest Of Middle East And Africa

11 . COMPETITIVE LANDSCAPE OF THE FAMILIAL AMYLOID POLYNEUROPATHY THERAPEUTICS COMPANIES
       11.1. Familial Amyloid Polyneuropathy Therapeutics Market Competition
       11.2. Partnership/Collaboration/Agreement
       11.3. Merger And Acquisitions
       11.4. New Product Launch
       11.5. Other Developments

12 . COMPANY PROFILES OF FAMILIAL AMYLOID POLYNEUROPATHY THERAPEUTICS INDUSTRY
       12.1. Company Share Analysis
       12.2. Market Concentration Rate
       12.3. Pfizer Inc.
           12.3.1. Company Overview
           12.3.2. Financials
           12.3.3. Products
           12.3.4. Recent Developments
       12.4. Alnylam Pharmaceuticals Inc.
           12.4.1. Company Overview
           12.4.2. Financials
           12.4.3. Products
           12.4.4. Recent Developments
       12.5. Ionis Pharmaceuticals Inc.
           12.5.1. Company Overview
           12.5.2. Financials
           12.5.3. Products
           12.5.4. Recent Developments
       12.6. Corino Therapeutics Inc.
           12.6.1. Company Overview
           12.6.2. Financials
           12.6.3. Products
           12.6.4. Recent Developments
       12.7. Proclara Biosciences
           12.7.1. Company Overview
           12.7.2. Financials
           12.7.3. Products
           12.7.4. Recent Developments
       12.8. Arcturus Therapeutics Inc.
           12.8.1. Company Overview
           12.8.2. Financials
           12.8.3. Products
           12.8.4. Recent Developments

*Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

LIST OF FIGURES

* Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

Choose your Buying Option

Single User License: $ 3950.00

Upto 10 Users License: $ 4950.00

Enterprise License: $ 8600.00

Data Pack: $ 2100.00

Buy Now

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

Buy sections of this report
Buy country level reports
Request for historical data
Request discounts available for Start-Ups & Universities

Request for Special Pricing

Objectives of Study

Define and measure the global market
Volume or revenue forecast of the global market and its various sub-segments with respect to main geographies
Analyze and identify major market trends along with the factors driving or inhibiting the market growth
Study the company profiles of the major market players with their market share
Analyze competitive developments

Why Choose Us

Client First Policy

Excellent Quality

After Sales Support

24/7 Email Support

Clients

Testimonials

" Doing business with Value Market Research was – quick, easy and accurate. We got what we expected. The team was very helpful and processes were altered for our convenience. The whole process from understanding our niche requirements to delivery to after sales was excellent. "

Vincenzo Baydar – Head Planning, Leading Food Chain, US

" Excellent work!! Working with you has been easy and direct. Your flexibility to alter the report scope and timely delivery assisted me in delivering my project proposal on time. "

Mia Tang, Director - Business Strategy, Steel Industry, Germany

" This is our second purchase and we have been obliged by the service. We appreciate the efforts put by Value Market Research in terms of understanding our needs, expanding the scope of the study, delivery and handling after sales queries. "